

## ABSTRACT

Neurosurgery. 2022 Aug 19. doi: 10.1227/neu.0000000000002093. Online ahead of print.

Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort.

Fadel HA(1), Haider S(1), Pawloski JA(1), Zakaria HM(1), Macki M(1), Bartlett S(2), Schultz L(1)(3), Robin AM(1), Kalkanis SN(1), Lee IY(1).

Author information:

(1)Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan, USA.

(2)Wayne State University School of Medicine, Detroit, Michigan, USA.

(3)Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA.

**BACKGROUND:** Laser interstitial thermal therapy (LITT) for glioblastoma (GBM) has been reserved for poor surgical candidates and deep "inoperable" lesions. We present the first reported series of LITT for surgically accessible recurrent GBM (rGBM) that would otherwise be treated with surgical resection.

**OBJECTIVE:** To evaluate the use of LITT for unifocal, lobar, first-time rGBM compared with a similar surgical cohort.

**METHODS:** A retrospective institutional database was used to identify patients with unifocal, lobar, first-time rGBM who underwent LITT or resection between 2013 and 2020. Clinical and volumetric lesional characteristics were compared between cohorts. Subgroup analysis of patients with lesions  $\leq 20$  cm<sup>3</sup> was also completed. Primary outcomes were overall survival and progression-free survival.

**RESULTS:** Of the 744 patients with rGBM treated from 2013 to 2020, a LITT cohort of 17 patients were compared with 23 similar surgical patients. There were no differences in baseline characteristics, although lesions were larger in the surgical cohort (7.54 vs 4.37 cm<sup>3</sup>,  $P = .017$ ). Despite differences in lesion size, both cohorts had similar extents of ablation/resection (90.7% vs 95.1%,  $P = .739$ ). Overall survival (14.1 vs 13.8 months,  $P = .578$ ) and progression-free survival (3.7 vs 3.3 months,  $P = 0.495$ ) were similar. LITT patients had significantly shorter hospital stays (2.2 vs 3.0 days,  $P = .004$ ). Subgroup analysis of patients with lesions  $\leq 20$  cm<sup>3</sup> showed similar outcomes, with LITT allowing for significantly shorter hospital stays.

**CONCLUSION:** We found no difference in survival outcomes or morbidity between LITT and repeat surgery for surgically accessible rGBM while LITT resulted in shorter hospital stays and more efficient postoperative care.

Copyright © Congress of Neurological Surgeons 2022. All rights reserved.

DOI: 10.1227/neu.0000000000002093

PMID: 35986677